GlassScriptPhysician profile
Shandell L Kidd
NPI 1598547341
$4,580.51
in general payments reported to CMS, 2019-2025
22 companies · $2,183 in 2025
The $2,183 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $148 · 2024: $2,249 · 2025: $2,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241 · Long Term Medical Supply Or Device Loan: $1,780 · Consulting Fee: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.80 |
| Long Term Medical Supply Or Device Loan | $1,779.71 |
| Consulting Fee | $560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,779.71 | 2024-2025 | |
| Gilead Sciences, INC. | $574.94 | 2024-2025 | Trodelvy |
| Genentech USA, INC. | $560.00 | 2024 | Itovebi |
| Astrazeneca Pharmaceuticals LP | $329.69 | 2024-2025 | Enhertu, Imfinzi, Lynparza |
| Lilly USA, LLC | $200.82 | 2023-2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $166.02 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Merck Sharp & Dohme LLC | $154.92 | 2024-2025 | Keytruda, Lynparza |
| Stemline Therapeutics INC. | $123.75 | 2025 | Orserdu |
| Daiichi Sankyo INC. | $115.16 | 2025 | Datroway, Enhertu |
| Tempus Ai, INC | $114.20 | 2024-2025 | Xt Cdx |
| Janssen Biotech, INC. | $80.00 | 2024-2025 | Erleada, Darzalex, Talvey |
| Genzyme Corporation | $71.52 | 2024-2025 | |
| Caris Mpi, INC. | $51.64 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $49.60 | 2024 | Myrisk |
| Incyte Corporation | $39.73 | 2025 | Zynyz, Niktimvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $32.05 | 2024 | Zoladex |
| Exelixis INC. | $30.19 | 2024 | Cabometyx |
| Adaptive Biotechnologies Corporation | $25.30 | 2025 | Clonoseq |
| Menarini Silicon Biosystems, INC. | $25.25 | 2024 | |
| Pharmacosmos Therapeutics INC. | $22.63 | 2025 | Monoferric |
| Celgene Corporation | $18.71 | 2025 | Breyanzi |
| Ferring Pharmaceuticals INC. | $14.68 | 2024 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shandell Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.